Developer docs
API playgroundTry for free, no card

Search company profiles

Q3 Medical Devices

Full company profile

uuid0003us7

Namestring
Q3 Medical Devices
Legal namestring
Q3 Medical Group
Websiteurl
q3medical.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Q3 Medical Group is an Ireland-based privately held medical device holding company that develops, manufactures, and commercializes biodegradable and minimally invasive catheter-based implant technologies for interventional cardiology, peripheral vascular, and non-vascular (primarily biliary and pancreatic) applications. The group operates four wholly owned subsidiaries — QualiMed Innovative Medizinprodukte GmbH and AMG International GmbH (both founded 1997 in Germany for manufacturing and channel respectively), Q3 Medical Devices (Shanghai) Co. Ltd. (Q-San, China manufacturing), and QualiMed USA, LLC (Charlotte, North Carolina, US market entry) — and was assembled by a consortium of medical device entrepreneurs, manufacturers, distributors, clinicians, and investors.

The company's product architecture spans three technology platforms. The biodegradable platform centers on a magnesium-and-polymer hybrid stent chemistry that supports the ARCHIMEDES biliary and pancreatic stent (the world's first CE-approved bioresorbable replacement for plastic biliary stents) and the UNITY-B family of percutaneous and endoscopic balloon expandable biodegradable biliary stents, both designed to eliminate removal procedures and mitigate the in-growth, over-growth, and perforation complications associated with traditional metal stents. The Mini Invasive Technologies platform delivers up to 6F-compatible peripheral vascular devices (PSpp self-expanding stent, QBX 35 balloon expandable stent, PVQ 35 and PVQ 35 HP PTA balloon catheters, and VX 6F aspiration catheter). The Micro Invasive Technologies platform covers 4F/5F devices used in procedures requiring minimal puncture site diameter. The portfolio is backed by more than 70 patents and utility models worldwide.

Revenue is generated through two parallel channels: branded product sales via AMG International's network of approximately 20 distributors reaching more than 30 countries across Europe, Asia, South America, and the Middle East, and OEM manufacturing for major global medical device companies (a legacy of QualiMed's founding role). The group holds CE approvals for mechanical implants, catheter-based technologies, drug-device combination products, and biodegradable technologies, and is pursuing US FDA IDE clearance for ARCHIMEDES via its Charlotte subsidiary. Strategic investors include China Pioneer Pharma Holdings (HKEX: 1345) and Boill Holding Group. Within the addressable interventional cardiology, peripheral vascular, and non-vascular markets (described as $20B+), the company is targeting replacement of 1.5 million annual plastic biliary stents globally and 500,000 in the US alone.

Short descriptiontext

Ireland-based medical device holding company developing biodegradable and minimally invasive catheter-based implants for biliary, pancreatic, peripheral vascular, and coronary applications, with own-branded and OEM distribution through subsidiaries in Germany, China, and the US across 30+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biodegradable stents, minimally invasive devices, endoscopic stents, vascular medical devices, percutaneous medical devices
Industry2 codes
PRIMARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAM
Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeOne Time License
Description

Q3 Medical Group generates revenue through the sale of its own branded medical device products (biodegradable stents, balloon catheters, aspiration catheters, and stent systems) across interventional cardiology, peripheral vascular, and non-vascular specialties. The group also operates as an OEM manufacturer designing and producing implantable stent devices for major global medical device companies.

q3medical.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Supply Chain, Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1ARCHIMEDES
Description

Biodegradable Biliary and Pancreatic Stent - World's first CE approved Bioresorbable replacement for plastic biliary stents.

q3medical.com
+3 more records
Core offering1 text field

Q3 Medical Devices is a medical device manufacturer focused on biodegradable stents and minimally invasive medical technologies. The company develops and produces stent products for endoscopic and percutaneous clinical applications, sold under multiple branded product lines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Eliminates removal procedures required for plastic stents at maximum 90 days post-implant, removing $5,000-$10,000 US facility fees per removal
+2 more records
Product overview1 text field

Q3 Medical Group is a medical device company organized as a platform-plus-modules architecture. The company operates through three main product platforms: Biodegradable Technologies (including ARCHIMEDES and UNITY-B biodegradable stents), Mini Invasive Technologies (up to 6F devices including stents, balloons, and aspiration catheters), and Micro Invasive Technologies (4F/5F devices). The biodegradable product line (ARCHIMEDES, UNITY-B Endoscopic, UNITY-B Percutaneous) focuses on biliary and pancreatic applications with the key benefit of eliminating removal procedures. The peripheral vascular product line (PSpp, QBX 35, PVQ 35, PVQ 35 HP, VX 6F) addresses broader vascular interventions. The company also maintains manufacturing operations through QualiMed (Germany), Q-San China, and Q3 Medical USA, supporting both proprietary branded products and OEM manufacturing capabilities.

Product and service7 records
1ARCHIMEDES
CategoryMedical Devices
Description

Biodegradable stent product in Q3 Medical Devices' portfolio.

2UNITY-B (Endoscopic & Percutaneous)
CategoryMedical Devices
Description

Biodegradable stent offering available in endoscopic and percutaneous delivery variants for minimally invasive implantation.

3PSpp
CategoryMedical Devices
Description

Stent product within Q3 Medical Devices' portfolio.

4QBX 35
CategoryMedical Devices
Description

Stent product within Q3 Medical Devices' portfolio.

5PVQ 35
CategoryMedical Devices
Description

Stent product within Q3 Medical Devices' portfolio.

6PVQ 35 HP
CategoryMedical Devices
Description

Stent product within Q3 Medical Devices' portfolio.

7VX
CategoryMedical Devices
Description

Product within Q3 Medical Devices' portfolio.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthers
Description

Eric K Mangiardi, President & CEO of Q3 Medical Group, previously founded Alveolus which was acquired by Merit Medical and now forms the foundation of their Merit Endotek Division. This represents a past acquisition of a company led by Q3 leadership, not an active partnership.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global interventional systems and stent manufacturer with overlapping peripheral vascular and access product lines serving similar accounts.

TypeDirect peer
Description

Specialises in aspiration and thrombectomy catheters (e.g., Indigo), making it a direct peer to Q3's VX 6F aspiration catheter in coronary and peripheral thrombus removal.

TypeDirect peer
Description

Operates in peripheral vascular disease and oncology intervention with comparable catheter and stent products targeting similar clinical accounts.

4Cook Medical
TypeDirect peer
Description

Established leader in GI and biliary stenting, directly competing with ARCHIMEDES and UNITY-B in endoscopic and percutaneous biliary applications.

TypeDirect peer
Description

Acquired Alveolus (founded by Q3's current CEO), which now forms the Merit Endotek Division. Directly comparable in peripheral vascular stents, aspiration catheters, and GI non-vascular devices.

TypeBroad incumbent
Description

Broad medical devices player with meaningful peripheral vascular and surgical franchises that overlap with Q3's minimally invasive portfolio.

TypeBroad incumbent
Description

Broad interventional cardiology, peripheral vascular, and GI portfolio; overlaps with Q3 across stents, PTA balloons, and biliary products as an established incumbent.

TypeBroad incumbent
Description

Major player in interventional cardiology and peripheral vascular devices, competing head-on with Q3's coronary and peripheral stent portfolio.

TypeBroad incumbent
Description

Dominant position in GI endoscopy where ARCHIMEDES and UNITY-B are deployed; competes for ERCP and biliary drainage procedure share.

TypeBroad incumbent
Description

Historical reference point in bioresorbable scaffolds (Absorb); competes broadly in coronary stents and vascular intervention against Q3.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Q3 Medical Devices

Medical Devicesq3medical.com

Ireland-based medical device holding company developing biodegradable and minimally invasive catheter-based implants for biliary, pancreatic, peripheral vascular, and coronary applications, with own-branded and OEM distribution through subsidiaries in Germany, China, and the US across 30+ countries.

What Q3 Medical Devices does

Q3 Medical Group is an Ireland-based privately held medical device holding company that develops, manufactures, and commercializes biodegradable and minimally invasive catheter-based implant technologies for interventional cardiology, peripheral vascular, and non-vascular (primarily biliary and pancreatic) applications. The group operates four wholly owned subsidiaries — QualiMed Innovative Medizinprodukte GmbH and AMG International GmbH (both founded 1997 in Germany for manufacturing and channel respectively), Q3 Medical Devices (Shanghai) Co. Ltd. (Q-San, China manufacturing), and QualiMed USA, LLC (Charlotte, North Carolina, US market entry) — and was assembled by a consortium of medical device entrepreneurs, manufacturers, distributors, clinicians, and investors.

The company's product architecture spans three technology platforms. The biodegradable platform centers on a magnesium-and-polymer hybrid stent chemistry that supports the ARCHIMEDES biliary and pancreatic stent (the world's first CE-approved bioresorbable replacement for plastic biliary stents) and the UNITY-B family of percutaneous and endoscopic balloon expandable biodegradable biliary stents, both designed to eliminate removal procedures and mitigate the in-growth, over-growth, and perforation complications associated with traditional metal stents. The Mini Invasive Technologies platform delivers up to 6F-compatible peripheral vascular devices (PSpp self-expanding stent, QBX 35 balloon expandable stent, PVQ 35 and PVQ 35 HP PTA balloon catheters, and VX 6F aspiration catheter). The Micro Invasive Technologies platform covers 4F/5F devices used in procedures requiring minimal puncture site diameter. The portfolio is backed by more than 70 patents and utility models worldwide.

Revenue is generated through two parallel channels: branded product sales via AMG International's network of approximately 20 distributors reaching more than 30 countries across Europe, Asia, South America, and the Middle East, and OEM manufacturing for major global medical device companies (a legacy of QualiMed's founding role). The group holds CE approvals for mechanical implants, catheter-based technologies, drug-device combination products, and biodegradable technologies, and is pursuing US FDA IDE clearance for ARCHIMEDES via its Charlotte subsidiary. Strategic investors include China Pioneer Pharma Holdings (HKEX: 1345) and Boill Holding Group. Within the addressable interventional cardiology, peripheral vascular, and non-vascular markets (described as $20B+), the company is targeting replacement of 1.5 million annual plastic biliary stents globally and 500,000 in the US alone.

Q3 Medical Devices firmographics

Firmographics
Name
Q3 Medical Devices
Legal name
Q3 Medical Group
Website
https://q3medical.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
Ireland-based medical device holding company developing biodegradable and minimally invasive catheter-based implants for biliary, pancreatic, peripheral vascular, and coronary applications, with own-branded and OEM distribution through subsidiaries in Germany, China, and the US across 30+ countries.
Ownership category
akta.pro rank

Q3 Medical Devices industry classification

Industry
Product category
Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAM
Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Biodegradable stents
  • Minimally invasive devices
  • Endoscopic stents
  • Vascular medical devices
  • Percutaneous medical devices

Where Q3 Medical Devices is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices4 records

Markets served

Q3 Medical Devices business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations

Revenue model

  1. Medical Device Sales: Q3 Medical Group generates revenue through the sale of its own branded medical device products (biodegradable stents, balloon catheters, aspiration catheters, and stent systems) across interventional cardiology, peripheral vascular, and non-vascular specialties. The group also operates as an OEM manufacturer designing and producing implantable stent devices for major global medical device companies.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels1 record

Q3 Medical Devices product offering

Product offering

Core offering

Q3 Medical Devices is a medical device manufacturer focused on biodegradable stents and minimally invasive medical technologies. The company develops and produces stent products for endoscopic and percutaneous clinical applications, sold under multiple branded product lines.

Product overview

Q3 Medical Group is a medical device company organized as a platform-plus-modules architecture. The company operates through three main product platforms: Biodegradable Technologies (including ARCHIMEDES and UNITY-B biodegradable stents), Mini Invasive Technologies (up to 6F devices including stents, balloons, and aspiration catheters), and Micro Invasive Technologies (4F/5F devices). The biodegradable product line (ARCHIMEDES, UNITY-B Endoscopic, UNITY-B Percutaneous) focuses on biliary and pancreatic applications with the key benefit of eliminating removal procedures. The peripheral vascular product line (PSpp, QBX 35, PVQ 35, PVQ 35 HP, VX 6F) addresses broader vascular interventions. The company also maintains manufacturing operations through QualiMed (Germany), Q-San China, and Q3 Medical USA, supporting both proprietary branded products and OEM manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • ARCHIMEDES: Biodegradable Biliary and Pancreatic Stent - World's first CE approved Bioresorbable replacement for plastic biliary stents.
  • UNITY-B
  • MINI Invasive Technologies
  • MICRO Invasive Technologies

Products and services

  • ARCHIMEDES Biodegradable stent product in Q3 Medical Devices' portfolio.
  • UNITY-B (Endoscopic & Percutaneous) Biodegradable stent offering available in endoscopic and percutaneous delivery variants for minimally invasive implantation.
  • PSpp Stent product within Q3 Medical Devices' portfolio.
  • QBX 35 Stent product within Q3 Medical Devices' portfolio.
  • PVQ 35 Stent product within Q3 Medical Devices' portfolio.
  • PVQ 35 HP Stent product within Q3 Medical Devices' portfolio.
  • VX Product within Q3 Medical Devices' portfolio.

Quantifiable outcome

  • Eliminates removal procedures required for plastic stents at maximum 90 days post-implant, removing $5,000-$10,000 US facility fees per removal
  • +2 more outcomes

Companies that use Q3 Medical Devices

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Q3 Medical Devices technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Q3 Medical Devices partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Merit MedicalminorOthersEric K Mangiardi, President & CEO of Q3 Medical Group, previously founded Alveolus which was acquired by Merit Medical and now forms the foundation of their Merit Endotek Division. This represents a past acquisition of a company led by Q3 leadership, not an active partnership.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Q3 Medical Devices competitors and assessment

Company assessment

Broad incumbents

  • Terumo: Global interventional systems and stent manufacturer with overlapping peripheral vascular and access product lines serving similar accounts.
  • Becton, Dickinson and Company (BD): Broad medical devices player with meaningful peripheral vascular and surgical franchises that overlap with Q3's minimally invasive portfolio.
  • Boston Scientific: Broad interventional cardiology, peripheral vascular, and GI portfolio; overlaps with Q3 across stents, PTA balloons, and biliary products as an established incumbent.
  • Medtronic: Major player in interventional cardiology and peripheral vascular devices, competing head-on with Q3's coronary and peripheral stent portfolio.
  • Olympus (Medical): Dominant position in GI endoscopy where ARCHIMEDES and UNITY-B are deployed; competes for ERCP and biliary drainage procedure share.
  • Abbott (Cardiovascular): Historical reference point in bioresorbable scaffolds (Absorb); competes broadly in coronary stents and vascular intervention against Q3.

Direct peers

  • Penumbra: Specialises in aspiration and thrombectomy catheters (e.g., Indigo), making it a direct peer to Q3's VX 6F aspiration catheter in coronary and peripheral thrombus removal.
  • AngioDynamics: Operates in peripheral vascular disease and oncology intervention with comparable catheter and stent products targeting similar clinical accounts.
  • Cook Medical: Established leader in GI and biliary stenting, directly competing with ARCHIMEDES and UNITY-B in endoscopic and percutaneous biliary applications.
  • Merit Medical Systems: Acquired Alveolus (founded by Q3's current CEO), which now forms the Merit Endotek Division. Directly comparable in peripheral vascular stents, aspiration catheters, and GI non-vascular devices.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Q3 Medical Devices social profiles

Digital presence

Q3 Medical Devices financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Q3 Medical Devices leadership team

Management profile

Number of profiles

Q3 Medical Devices subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Q3 Medical Devices funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Q3 Medical Devices M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Q3 Medical Devices

What does Q3 Medical Devices do?

Q3 Medical Devices is a medical device manufacturer focused on biodegradable stents and minimally invasive medical technologies. The company develops and produces stent products for endoscopic and percutaneous clinical applications, sold under multiple branded product lines.

Is Q3 Medical Devices a public or private company?

Q3 Medical Devices is a private company. It is classified as unknown and is currently operating.

When was Q3 Medical Devices founded?

Q3 Medical Devices was founded in 2013. It employs 101 to 250 people.

Where is Q3 Medical Devices based?

Q3 Medical Devices is headquartered in Dublin, Ireland, in the Europe region.

How does Q3 Medical Devices make money?

One revenue line is on record: medical Device Sales.

Who are Q3 Medical Devices's main competitors?

Broad incumbents on record are Terumo, Becton, Dickinson and Company (BD), Boston Scientific, Medtronic, Olympus (Medical) and Abbott (Cardiovascular). Direct peers are Penumbra, AngioDynamics, Cook Medical and Merit Medical Systems.

Does Q3 Medical Devices have an API?

No public API is recorded for Q3 Medical Devices.

What industry is Q3 Medical Devices in?

Q3 Medical Devices's product category is Medical Devices. Its primary akta.pro industry code is HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS), with a secondary code of HLAHADAM, Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireQualiMed Innovative Medizinprodukte GmbH, a Q3 Medical Devices Ltd Company, Receives European CE Mark Approval for UNITY-B™ Percutaneous Balloon Expandable Biodegradable Biliary StentQualiMed received CE mark approval for its UNITY-B biodegradable biliary stent, designed to replace non-degradable metal implants. The device achieved a 94.4% clinical success rate in a study, with no adverse events reported. The company plans to develop additional biodegradable products for gastrointestinal and vascular applications.PR NewswireQ3 Medical Devices Leads the Way for Irish Companies Seeking to List on Hong Kong ExchangeQ3 Medical Devices Limited, a Dublin-based medical device holding company, announced that the Hong Kong Stock Exchange has approved Ireland as an acceptable jurisdiction for Irish companies seeking to list on the Exchange. The approval, granted on December 19, 2019 following discussions between Q3 Medical, its advisors, the Exchange, and regulatory authorities, enables Q3 Medical to proceed with its planned initial public offering on the Hong Kong Stock Exchange. The company aims to become the first Irish company listed on the Exchange, representing a milestone for Irish businesses seeking access to Asian capital markets.PR Newswireamg International GmbH Performs First Clinical Cases in Europe with New Biodegradable Biliary/Pancreatic Stent Since Receiving CE Mark in Juneamg International GmbH, a wholly owned subsidiary of Q3 Medical Devices Limited, announced the completion of first European clinical cases with its ARCHIMEDES fully biodegradable biliary/pancreatic stent following CE Mark approval in June 2018. The biodegradable stent eliminates the secondary removal procedure required by traditional plastic stents, addressing complications that occur in up to 30% of traditional stent placements. The initial cases were performed across five clinical sites in Spain, Italy, and Finland, demonstrating the stent's versatility across various clinical indications including prophylactic placement alongside metal stents, serial placement after stone removal, and maintenance of choledochal stenosis patency.PR NewswireQ3 Medical Devices Ltd. and the Boill Group Continue Expansion Plans in ChinaQ3 Medical Devices Ltd. and the Boill Holding Group met with Baoshan district officials in China on April 19, 2018, to discuss their joint investment in a high-tech medical device manufacturing and R&D facility in the region. The facility, located in the Boill E Wisdom Valley Industrial Park, is expected to open within the next year and will focus on bioresorbable, micro-invasive medical devices for interventional cardiology, peripheral vascular, and non-vascular diseases. Q3 Medical operates through four wholly owned subsidiaries in the United States, Germany, and China, while Boill Holding Group serves as the lead investor with over 12 billion RMB in assets.